EGFR and cancer: Activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR) drive the growth of 10–30% of non-small cell lung cancers (NSCLCs), the leading cause of cancer mortality worldwide with a five-year survival rate of 23% [1].